Abstract: The present invention provides a Plexin-binding regulating agent containing a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt of the cyclic peptide.

Abstract: Provided are: an antibody which specifically binds to and neutralizes USAG-1 or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or the antigen-binding fragment.

Abstract: The present invention provides a method for producing a substance with a modified carbon allotrope surface that can suppress or prevent uneven distribution, uneven orientation, and the like of a structural analysis target substance in a structural analysis by cryo-electron microscopy. A method for producing a substance with a modified carbon allotrope surface of the present invention includes: the step of surface-treating by reacting a carbon allotrope surface with a halogen oxide radical, wherein the carbon allotrope surface is modified by the surface-treating.

Abstract: A method for producing a Wnt protein-afamin complex, the method comprising the steps of culturing Wnt protein-expressing cells in a culture medium containing a purified afamin or a recombinant afamin or co-culturing Wnt protein-expressing cells and recombinant afamin-expressing cells or culturing cells expressing both a Wnt protein and afamin; obtaining the culture supernatant; and optionally performing affinity purification to obtain the Wnt protein-afamin complex from the culture supernatant.

Abstract: A base station includes: a transmitter configured to transmit an operation signal for a remote control; and a controller that is coupled to the transmitter, wherein the controller is configured to execute a setting process that includes setting, with regard to transmission of the operation signal, a service class for the remote control, wherein the service class for the remote control includes a Packet Delay Budget (PDB) which is set to 5 milliseconds, and execute a control process that includes controlling, in accordance with the service class, the operation signal to be transmitted via the transmitter, wherein the transmitter is configured to transmit the operation signal by using the service class that is set to the operation signal and information associated with the operation signal, wherein the information relates to a first attribute value that is different from a value of at least one attribute associated with the service class.

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.

Abstract: A control apparatus includes: a network interface configured to perform transmission and reception of a signal; a controller coupled to the network interface, the controller configured to execute transfer processing that includes transferring service class information indicating a service class for controlling a remote device, execute setting processing that includes setting the service class to transmission of an operation signal for controlling the remote device, and execute control processing that includes controlling transfer of the operation signal via the network interface by using the service class. The control processing is configured to control transfer of the operation signal by using the service class that is set to the operation signal and information that is associated with the operation signal. The information relates to a first attribute value different from a value of at least one attribute associated with the service class.

Abstract: The purpose of the present invention is to provide an efficient and versatile method for granting an additional binding activity to an antibody by inserting a peptide sequence into the antibody. The present invention provides a method of granting a binding ability to a second target molecule to an antibody, comprising inserting an internal peptide sequence of a cyclic peptide into an Fc region of the antibody, wherein the cyclic peptide has the binding ability to the second target molecule different from a first target molecule to be recognized by the antibody.

Abstract: The purpose of the present invention is to provide an artificial protein having a bioactive peptide fused with a site, of a protein having at least an antigen binding region of an antibody, present in a folded portion of a secondary structure in a structural region having an antigen-binding activity and exposed on a surface of the protein.

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.

Abstract: The present invention provides a method of presenting a cyclic peptide on a protein having a loop structure. The cyclic peptide has a chemically crosslinked structure for forming an intramolecular cyclic structure. The method includes replacing the chemically crosslinked structure of the cyclic peptide with two amino acid residues constituting the loop structure, thereby fusing the cyclic peptide with the protein having a loop structure.

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.

Abstract: A base station includes: a transmitter configured to transmit an operation signal for a remote control; and a controller that is coupled to the transmitter, wherein the controller is configured to execute a setting process that includes setting, with regard to transmission of the operation signal, a service class for the remote control, wherein the service class for the remote control includes a Packet Delay Budget (PDB) which is set to 5 milliseconds, and execute a control process that includes controlling, in accordance with the service class, the operation signal to be transmitted via the transmitter, wherein the transmitter is configured to transmit the operation signal by using the service class that is set to the operation signal and information associated with the operation signal, wherein the information relates to a first attribute value that is different from a value of at least one attribute associated with the service class.

Abstract: A control apparatus includes: a network interface configured to perform transmission and reception of a signal; a controller coupled to the network interface, the controller configured to execute transfer processing that includes transferring service class information indicating a service class for controlling a remote device, execute setting processing that includes setting the service class to transmission of an operation signal for controlling the remote device, and execute control processing that includes controlling transfer of the operation signal via the network interface by using the service class. The control processing is configured to control transfer of the operation signal by using the service class that is set to the operation signal and information that is associated with the operation signal. The information relates to a first attribute value different from a value of at least one attribute associated with the service class.

Abstract: A base station includes: a transmitter configured to transmit an operation signal for a remote control; and a controller that is coupled to the transmitter, wherein the controller is configured to execute a setting process that includes setting, with regard to transmission of the operation signal, a service class for the remote control, and execute a control process that includes controlling, in accordance with the service class, the operation signal to be transmitted via the transmitter.

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.

Abstract: Provided is a novel method for producing a Wnt protein, which method comprises (1) a step of performing affinity purification targeting afamin to obtain a Wnt protein from a culture product, and/or (2) a step of performing affinity purification to obtain a Wnt protein in the form of a complex with afamin from a culture product. The method enables a Wnt protein having high Wnt activity to be produced in a simple and brief manner without use of special equipment.

Abstract: Provided is a novel method for producing a Wnt protein, which method comprises (1) a step of performing affinity purification targeting afamin to obtain a Wnt protein from a culture product, and/or (2) a step of performing affinity purification to obtain a Wnt protein in the form of a complex with afamin from a culture product. The method enables a Wnt protein having high Wnt activity to be produced in a simple and brief manner without use of special equipment.

Abstract: An object of the present invention is to provide a fragment antibody which can be conveniently produced as one having antigen-binding activity, and which has a greater ability to crystallize itself alone or as a complex with an antigen molecule than that of Fv-clasp (v1) even in a case where the fragment antibody is obtained in an E. coli expression system. The present invention relates to a fragment antibody including a complex of a peptide (VH(112C)-SARAH) in which an N-terminus of a SARAH domain is linked to a C-terminus of a heavy chain domain (VH region) of an antibody, and an amino acid residue of antibody residue 112 according to Chothia numbering scheme in the VH region is mutated to cysteine; and a peptide (VL-SARAH(37C)) in which an N-terminus of a SARAH domain is linked to a C-terminus of a light chain domain (VL region) of an antibody, and an amino acid residue at position 13 from the C-terminus in the SARAH domain is mutated to cysteine.